Urology News and Research

Latest Urology News and Research

Early diagnosis of interstitial cystitis can improve quality of life

October is interstitial cystitis (IC) awareness month and this year's campaign is dedicated to fighting discrimination.

5 Oct 2010

VIVUS announces divestiture of MUSE to Meda

VIVUS, Inc. today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED). Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

4 Oct 2010

Alexander Technique training program improves endurance and posture during surgery

A century-old posture improvement technique developed by Shakespearian actor F.M. Alexander to correct his chronic laryngitis appears to enhance the posture and proficiency of surgeons who perform minimally invasive procedures.

4 Oct 2010

Maven Semantic updates Urinary Incontinence research database

Maven Semantic announces updates to their Urinary Incontinence research database.

4 Oct 2010

Single-incision, robot surgery at UT Southwestern helps fix congenital narrowing of ureters

A stabbing pain in Cameron Giammalva's abdomen came on so suddenly one day during his freshman year of college that he and his friends mistook it for appendicitis.

4 Oct 2010

Researchers find link between arterial stiffness and diastolic function

Physicians have identified a risk factor for heart disease in adulthood that can be present in children as young as 10. They're also calling for screening for this risk factor to help motivate children to exercise and lose weight.

4 Oct 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

microRNA may provide quick diagnosis of bladder cancer

Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.

29 Sep 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Apax Partners today announced that Endo Pharmaceuticals has entered into a definitive agreement to acquire Qualitest Pharmaceuticals for approximately $1.2 billion in cash. Qualitest, a portfolio company of Apax Partners since 2007, is the sixth largest generic pharmaceutical company in the U.S.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

28 Sep 2010

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated in the trial.

28 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private placement. The notes are additional notes constituting a part of the same series as the $750 million aggregate principal amount of 7-3/4% senior notes due 2018 issued on August 20, 2010.

24 Sep 2010

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.

24 Sep 2010

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of a study "Percutaneous Tibial Nerve Stimulation Effects on Detrusor Overactivity Incontinence Are Not Due to a Placebo Effect A Randomized, Double-Blind, Placebo Controlled Trial," to be published in the November 2010 print edition of THE JOURNAL OF UROLOGY.

24 Sep 2010

Urology News and Research

Latest Urology News and Research

Early diagnosis of interstitial cystitis can improve quality of life

VIVUS announces divestiture of MUSE to Meda

Alexander Technique training program improves endurance and posture during surgery

Maven Semantic updates Urinary Incontinence research database

Single-incision, robot surgery at UT Southwestern helps fix congenital narrowing of ureters

Researchers find link between arterial stiffness and diastolic function

Warburg Pincus to invest CDN $35 million in Protox

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

microRNA may provide quick diagnosis of bladder cancer

New predictive test to identify aggressive prostate cancer

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in